AudioScholar Endocrinology Weekly

AudioScholar
  • 0.0 (0)
  • Medicine
  • Weekly

Endocrinology — a weekly podcast briefing of the most significant peer-reviewed endocrinology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc.

  1. 4d ago

    This Week in Endocrinology — Oct 28, 2026

    Editor's Pick: Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea (New England Journal of Medicine, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Endocrinology. This week we're covering 10 notable papers spanning the expanding reach of incretin-based therapies, drug safety and glycaemic risk in vulnerable diabetes populations, and hormone replacement across the lifespan… This week's papers: 1. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea. — New England Journal of Medicine 2026 2. A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Ago… — Diabetes Care 2026 3. Target Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis. — Diabetes Care 2026 4. Normal-BMI MASLD is Associated with Increased Mortality, Cardiovascular Events, Cancer and Lower GLP-1 Use. — Journal of Clinical Endocrinology & Metabolism 2026 5. Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Older Adults With Type 2 Diabetes: A Cohort Study. — Diabetes Care 2026 6. Long-term Glycemia and Risk of Death in Cystic Fibrosis-Related Diabetes: A UK Cystic Fibrosis Registry Study. — Diabetes Care 2026 7. Palopegteriparatide in Adults With Hypoparathyroidism: 3.5-Year Results From the Phase 3 PaTHway Trial. — Journal of Clinical Endocrinology & Metabolism 2026 8. Efficacy and Safety of Lonapegsomatropin in Children With Turner Syndrome: 52-Week Results From the New InsiGHTS Trial. — Journal of Clinical Endocrinology & Metabolism 2026 9. Debate: Level of TSH at which thyroid hormone replacement should be initiated in gestation. — Journal of Clinical Endocrinology & Metabolism 2026 10. Reappraising the safety of menopausal hormone therapy for women-implications for the clinic. — Journal of Clinical Endocrinology & Metabolism 2026 Listen at https://audioscholar.cc/episode/46rqnmxf7p

  2. Oct 22

    This Week in Endocrinology — Oct 21, 2026

    Editor's Pick: Continuous Glucose Monitoring in Non-Insulin-Treated Type 2 Diabetes (New England Journal of Medicine, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Endocrinology. This week we're covering 10 notable papers spanning the changing toolkit for type 2 diabetes, risk prediction from prediabetes through remission, the scaling of obesity pharmacotherapy, and refinements in adrena… This week's papers: 1. Continuous Glucose Monitoring in Non-Insulin-Treated Type 2 Diabetes. — New England Journal of Medicine 2026 2. Efficacy and safety of HRS-7535, a novel oral small-molecule glucagon-like peptide-1 receptor agonist, in participants with type 2 diabetes mellitus inadequate… — Diabetologia 2026 3. A Recipe for Better Diabetes Management: The DASH4D Dietary Pattern. — Diabetes Care 2026 4. Evolving phenotype of newly diagnosed type 2 diabetes: a 15-year population-based comparison. — Diabetologia 2026 5. Prediabetes subtype-based stratification reveals distinct long-term risks for type 2 diabetes. — Diabetologia 2026 6. Predictors of Type 2 Diabetes Remission and Relapse After Metabolic-Bariatric Surgery or Medical-Lifestyle Therapy in the ARMMS-T2D Study. — Diabetes Care 2026 7. Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women. — Nature Medicine 2026 8. The development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO. — The Lancet Diabetes & Endocrinology 2026 9. Diagnostic Utility of Diurnal Salivary Cortisol Profiles in Neoplastic and Non-Neoplastic Hypercortisolism. — European Journal of Endocrinology 2026 10. Precision Thyroid Oncology Using Genetic-Based Therapies: A Narrative Review. — Thyroid 2026 Listen at https://audioscholar.cc/episode/phmn8y539w

  3. Oct 15

    This Week in Endocrinology — Oct 14, 2026

    Editor's Pick: Risk-Stratified Outcomes Using the 2025 ATA Thyroglobulin Cutoff After Total Thyroidectomy in Differentiated Thyroid Cancer (Journal of Clinical Endocrinology & Metabolism, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Endocrinology. This week we're covering 10 notable papers spanning the real-world test of the 2025 American Thyroid Association guidance, adrenal and calcium problems from diagnosis to emergency care, and the widening metaboli… This week's papers: 1. Comparative Performance of the 2015 and 2025 American Thyroid Association Initial Recurrence Risk Stratification Systems in Differentiated Thyroid Cancer. — Thyroid 2026 2. Risk-Stratified Outcomes Using the 2025 ATA Thyroglobulin Cutoff After Total Thyroidectomy in Differentiated Thyroid Cancer. — Journal of Clinical Endocrinology & Metabolism 2026 3. Iopanoic Acid in Severe Thyrotoxicosis: Rediscovering an Effective Therapy. — Journal of Clinical Endocrinology & Metabolism 2026 4. Cortisol Cutoffs for Adrenal Insufficiency Using Elecsys II: A Systematic Review. — Clinical Endocrinology 2026 5. Mild Autonomous Cortisol Secretion and Psychiatric Morbidity in Patients With Adrenal Tumors: A Cohort Study. — Journal of Clinical Endocrinology & Metabolism 2026 6. Comparative Effectiveness of Denosumab Versus Bisphosphonates for Hypercalcemia of Malignancy: A Real-World Cohort Study. — Journal of Clinical Endocrinology & Metabolism 2026 7. Approach to a patient with MEN1 syndrome. — Journal of Clinical Endocrinology & Metabolism 2026 8. Preconception incretin therapy reduces pregnancy and cardiometabolic outcomes in polycystic ovary syndrome. — Journal of Clinical Endocrinology & Metabolism 2026 9. Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analy… — Journal of Clinical Endocrinology & Metabolism 2026 10. Contemporary Sex-Specific Mortality Risk in Type 1 Diabetes During the Era of Advanced Therapeutic Care. — Diabetes Care 2026 Listen at https://audioscholar.cc/episode/e4hzj53a7z

  4. Oct 8

    This Week in Endocrinology — Oct 7, 2026

    Editor's Pick: Management of Type 2 Diabetes, 2026. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (Diabetes Care, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Endocrinology. This week we're covering 10 notable papers spanning the reshaping of type 2 diabetes therapy, glucose monitoring and automation across both types of diabetes, and the management of prolactinoma around pregnancy.… This week's papers: 1. Management of Type 2 Diabetes, 2026. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD… — Diabetes Care 2026 2. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. — New England Journal of Medicine 2026 3. Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial. — Nature Medicine 2026 4. Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial. — Nature Medicine 2026 5. A Multicenter 13-Week Evaluation of the twiist Automated Insulin Delivery in Insulin-Treated Type 2 Diabetes: The twiist-T2D Pivotal Trial. — Diabetes Care 2026 6. Efficacy of the digital therapeutic glucura combined with CGM in the treatment of type 2 diabetes: a randomised controlled trial over 6 months. — Diabetologia 2026 7. CGM has Similar Predictive Performance to OGTT for Monitoring Early-Stage Type 1 Diabetes. — Journal of Clinical Endocrinology & Metabolism 2026 8. Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, ph… — The Lancet Diabetes & Endocrinology 2026 9. Approach to the pregnant patient with prolactinoma. — Journal of Clinical Endocrinology & Metabolism 2026 10. Nadir Prolactin-guided Individualized Cabergoline Therapy Achieves Durable Remission and Safe Pregnancy in Prolactinomas. — Journal of Clinical Endocrinology & Metabolism 2026 Listen at https://audioscholar.cc/episode/yx9ykuwg5t

  5. Oct 1

    This Week in Endocrinology — Sep 30, 2026

    Editor's Pick: Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial (The Lancet, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Endocrinology. This week we're covering 10 notable papers spanning the next generation of obesity and incretin pharmacotherapy, oral GLP-1 receptor agonists and their cardiovascular safety, and a set of studies on special popu… This week's papers: 1. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-dri… — The Lancet 2026 2. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. — New England Journal of Medicine 2026 3. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. — The Lancet 2026 4. Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial. — Nature Medicine 2026 5. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. — The Lancet Diabetes & Endocrinology 2026 6. Disease modification outcomes in type 2 diabetes: a modified Delphi. — The Lancet Diabetes & Endocrinology 2026 7. Safety of glucagon-like peptide-1 receptor agonists and other new-generation glucose-lowering agents for the management of type 2 diabetes in pregnancy: a Fren… — Diabetologia 2026 8. Trends in prevalence of type 2 diabetes and intermediate hyperglycaemia in Mauritius from 1987 to 2021 based on results from the oral glucose tolerance test: a… — The Lancet Diabetes & Endocrinology 2026 9. Glycemic and psychosocial outcomes of automated insulin delivery in older and high-risk populations with type 1 diabetes: a systematic review and meta-analysis. — Journal of Clinical Endocrinology & Metabolism 2026 10. Delayed time to stage 3 type 1 diabetes after GAD-alum treatment in HLA-DR3-DQ2-positive children: follow-up of the randomised placebo-controlled Diabetes Prev… — Diabetologia 2026 Listen at https://audioscholar.cc/episode/t3ptstgrs8

  6. Sep 24

    This Week in Endocrinology — Sep 23, 2026

    Editor's Pick: An International Position Statement on Practical Approaches for Inpatient Continuous Glucose Monitoring, Insulin Pumps, and Automated Insulin Delivery Systems in Adults (Diabetes Care, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Endocrinology. This week we're covering 10 notable papers spanning diabetes technology and cardiovascular risk, prevention and risk stratification across the life course, women's metabolic health, and a cluster of pituitary, a… This week's papers: 1. An International Position Statement on Practical Approaches for Inpatient Continuous Glucose Monitoring, Insulin Pumps, and Automated Insulin Delivery Systems… — Diabetes Care 2026 2. Multimodal Imaging for Adrenal Tumor Characterization: Clinical Impact of the 2023 European Guidelines - A Single-Center Retrospective Study. — European Journal of Endocrinology 2026 3. Effects of Empagliflozin on Cardiovascular Outcomes Are Consistent Across Sociodemographic Subgroups: A Real-World Analysis From the EMPRISE Study. — Diabetes Care 2026 4. Cardiovascular Morbidity in Acromegaly during a Long-term Follow-Up - a Nationwide Cohort Study. — European Journal of Endocrinology 2026 5. Association of Age at Type 1 Diabetes Onset With Survival, Cardiovascular, and Kidney Outcomes: A Nationwide Cohort Study. — Diabetes Care 2026 6. Menopause hormone therapy and type 2 diabetes risk and prognosis: systematic review and meta-analyses. — Diabetologia 2026 7. The effect of lifestyle interventions in women with polyendocrine metabolic ovarian syndrome: A systematic review and meta-analysis. — PLOS Medicine 2026 8. Association of a multiple risk factor assessment and intervention program with risk of diabetes: A population-based matched cohort study. — PLOS Medicine 2026 9. Pituitary adenomas in older patients - approaches, challenges and future directions. — European Journal of Endocrinology 2026 10. Leveraging Long-Read Sequencing to Bridge the Diagnostic and Equity Gaps in Differences of Sex Development (DSD). — Journal of Clinical Endocrinology & Metabolism 2026 Listen at https://audioscholar.cc/episode/hdd8gj2ef9

  7. Sep 17

    This Week in Endocrinology — Sep 16, 2026

    Editor's Pick: The Management of Type 1 Diabetes in Adults. The Updated 2026 Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (Diabetes Care, 2026) Welcome to This Week in Endocrinology. This week we're covering 10 notable papers spanning a cluster of major new consensus guidance in diabetes care, the emotional burden of living with diabetes, the diagnostic minefield of primary aldosteronism, an… This week's papers: 1. The Management of Type 1 Diabetes in Adults. The Updated 2026 Consensus Report by the American Diabetes Association (ADA) and the European Association for the… — Diabetes Care 2026 2. 2026 EASD evidence-based clinical practice guideline for assessing and managing diabetes distress among adults with type 1 diabetes or type 2 diabetes. — Diabetologia 2026 3. The Transition of Youth With Diabetes From Pediatric to Adult Diabetes Care Services: A Consensus Report of the Joint Working Group of the International Societ… — Diabetes Care 2026 4. Interpreting Serial Aldosterone-to-Renin Ratio Measurements in the Diagnostic Work-up of Primary Aldosteronism. — Journal of Clinical Endocrinology & Metabolism 2026 5. Must RAAS-modifying drugs be withdrawn for the diagnosis of primary aldosteronism? — Journal of Clinical Endocrinology & Metabolism 2026 6. Maternal and Neonatal Complications in Pregnant Women With Polyendocrine Metabolic Ovarian Syndrome: A Nested Prospective Cohort Study. — Diabetes Care 2026 7. Acromegalic Osteoarthropathy: A New Paradigm of Pathological Musculoskeletal Remodeling. — European Journal of Endocrinology 2026 8. Association between worsening time in range and microvascular complications in type 1 diabetes: real-world 5-year study. — Journal of Clinical Endocrinology & Metabolism 2026 9. Glucose excursions throughout the reproductive life stages in women with diabetes. — Journal of Clinical Endocrinology & Metabolism 2026 10. Interventions to reduce diabetes-related distress among adults with type 1 or type 2 diabetes: a systematic review and meta-analysis of randomised controlled t… — Diabetologia 2026 Listen at https://audioscholar.cc/episode/2u2hzjny4x

  8. Sep 10

    This Week in Endocrinology — Sep 9, 2026

    Editor's Pick: Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence (Journal of Clinical Endocrinology & Metabolism, 2026) Welcome to This Week in Endocrinology. This week we're covering 10 notable papers spanning diabetes complications and how we might actually modify them, the messy practicalities of cortisol testing and adrenal surgery, and the shifting landscape of r… This week's papers: 1. Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence. — Journal of Clinical Endocrinology & Metabolism 2026 2. Evaluating Improvement in Pain and Sensory Function When Using High-Frequency (10-kHz) Spinal Cord Stimulation in Individuals With Painful Diabetic Neuropathy:… — Diabetes Care 2026 3. SGLT Inhibitors for Heart and Kidney Disease in Type 1 Diabetes. — Diabetes Care 2026 4. Clinical and pharmacological determinants of serum dexamethasone concentrations during dexamethasone suppression test. — Journal of Clinical Endocrinology & Metabolism 2026 5. Approach to the Patient: Diagnosis and Management of Cushing's Syndrome in the Elderly - How Different Is It? — Journal of Clinical Endocrinology & Metabolism 2026 6. Glucocorticoid Replacement Duration After Unilateral Adrenalectomy for Mild Autonomous Cortisol Secretion and Adrenal Cushing Syndrome: A Multicenter Cohort St… — European Journal of Endocrinology 2026 7. Hypoparathyroidism: translating science from the laboratory to the clinic. — The Lancet Diabetes & Endocrinology 2026 8. Hospitalizations and outcomes in Congenital Adrenal Hyperplasia across the lifespan: A population-based cohort study. — Journal of Clinical Endocrinology & Metabolism 2026 9. Obesity science, research gaps, and opportunities in the new era of obesity medicines: an Endocrine Society scientific statement. — Endocrine Reviews 2026 10. Social inequalities in gestational diabetes prevalence and complication burden: a nationwide Swedish cohort study. — Journal of Clinical Endocrinology & Metabolism 2026 Listen at https://audioscholar.cc/episode/rebust625x

See All (25)

About

Endocrinology — a weekly podcast briefing of the most significant peer-reviewed endocrinology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc.

Information